Shukra Pharmaceuticals share news and announcements
NSE: SHUKRAPHARBSE: 524632Pharmaceuticals & BiotechnologySmall Cap
Share price at the NSE close on 23 Oct 2026. Previous close ₹62.53.
- Next results date: the board meets on 3 Nov 2026 to consider: financial results.
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies.
- ₹2,834 Cr1,258th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. The filing of 12 Aug 2026
- 78.6
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. The filing of 15 Jul 2026
- 31.5
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.02%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it. The filing of 12 Aug 2026
- 47.2%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet. The filing of 12 Aug 2026
- 47.3%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026. The filing of 15 Jul 2026
- 0.06
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day.
- 1,99,54,06817.8% delivered
Next board meeting and results date
As the company gave notice to the exchange.Shukra Pharmaceuticals quarterly results
The board meets on 4 Nov 2026 to consider financial results
Notice filed 23 Oct 2026
Shukra Pharmaceuticals annual reports, presentations and earnings calls
The company's own documents, latest first.Shukra Pharmaceuticals financials, year by year
Annual reports1
Shukra Pharmaceuticals share news and announcements
79 announcements, routine notices left out, newest first. Page 1 of 2.
Oct 2026
22 Oct · Board meeting
Not held on this date
6 Oct · Board meeting
6 Oct · Legal
Significant movement in price has been observed in Shukra Pharmaceuticals Limited. The Exchange, in order to ensure that investors have latest relevant information about the company and to inform the market place so that the interest of the investors is safeguarded, has written to the company. The response from the company is awaited.
Sep 2026
28 Sep · Board meeting
22 Sep · Meeting
18 Sep · Corporate action
2 Sep · Board meeting
Aug 2026
27 Aug · Meeting
22 Aug · Board meeting
17 Aug · Board meeting
12 Aug · Results
Jul 2026
6 Jul · Results
Jun 2026
12 Jun · Meeting
May 2026
7 May · Announcement under Regulation 30 (LODR)-Allotment
Feb 2026
Jan 2026
28 Jan · Announcement under Regulation 30 (LODR)-Allotment
5 Jan · Meeting
Dec 2025
30 Dec · Reconstitution Of Committees Of The Company.
30 Dec · Board meeting
22 Dec · Intimation For Corporate Announcement Under Regulation 30 Of SEBI (LODR) Regulations, Working In The Government Market Of Gujarat For Our Laparoscopic Sets And Accessories.
Nov 2025
29 Nov · Approval Of Continuation Of Directorship Of Mr. Jitendra Somchand Shah Non-Executive Independent Director Who Has Attained Age Of 75 Years On September 22, 2025 Subject To Approval Of Shareholders.
29 Nov · Outcome Of The Meeting Of The Board Of Directors Held On Saturday, November 29, 2025
13 Nov · Results
10 Nov · Intimation Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 - Incorporation Of Subsidiary Company.
How the price met the news
The first session after each announcement, beside the market. Moves to 16 Jun 2026 are on BSE closes, before the company traded on NSE.
That dayThe first session's move. The first session's close after the announcement against the close before it, as a per cent change, on prices adjusted for splits and bonuses.Against the Nifty 500Against the Nifty 500. The share's move less the Nifty 500's move the same session, in percentage points (pts).Market median on that newsThe market's median move on that news. The middle first-session move of every listed company that filed the same kind of announcement, half moving more and half less.Five sessionsFive sessions' move. The close five sessions after the announcement against the close before it, as a per cent change.Five sessions against the Nifty 500Five sessions against the Nifty 500. The share's five-session move less the Nifty 500's move over the same five sessions, in percentage points (pts).Volume, times usualVolume, times usual. The session's shares traded divided by the average of the twenty sessions before it.
- 16 Jun 2026Board or managers changedup 0.35%−0.1 pts vs Nifty 500market median 0.0% · five sessions −4.3% (−5.9 pts vs Nifty 500) · volume 0.5× usual · The announcement (opens in a new tab)
- 8 May 2026Dividenddown 4.99%−4.6 pts vs Nifty 500market median 0.0% · five sessions −8.7% (−6.1 pts vs Nifty 500) · volume 2.4× usual · The announcement (opens in a new tab)
- 31 Dec 2025Board or managers changeddown 4.99%−5.8 pts vs Nifty 500market median 0.0% · five sessions −17.5% (−18.9 pts vs Nifty 500) · volume 0.8× usual · The announcement (opens in a new tab)
- 3 Dec 2025Order receiveddown 1.24%−0.8 pts vs Nifty 500market median +1.1% · five sessions +13.9% (+15.2 pts vs Nifty 500) · volume 0.5× usual · The announcement (opens in a new tab)
- 15 Sep 2025Dividendup 1.98%+1.9 pts vs Nifty 500market median 0.0% · five sessions +10.3% (+9.0 pts vs Nifty 500) · volume 0.3× usual · The announcement (opens in a new tab)
- 29 Aug 2025Order receivedup 1.98%+2.3 pts vs Nifty 500market median +1.1% · five sessions +10.3% (+9.1 pts vs Nifty 500) · volume 1.7× usual · The announcement (opens in a new tab)
- 30 Jun 2025Order receivedup 4.98%+5.0 pts vs Nifty 500market median +1.1% · five sessions +27.5% (+27.7 pts vs Nifty 500) · volume 1.1× usual · The announcement (opens in a new tab)
- 5 Jun 2025Dividendup 1.96%+1.4 pts vs Nifty 500market median 0.0% · five sessions +10.3% (+7.9 pts vs Nifty 500) · volume 0.5× usual · The announcement (opens in a new tab)
Figures filed again
Lines the company later filed with a different value, rupee lines in ₹ crore and per-share lines in rupees.
| Line | Period | Accounts | First filed | Filed again | Change. The value filed again less the value first filed, as a per cent of the first. | First filed on | Filed again on |
|---|---|---|---|---|---|---|---|
| Materials used | Quarter to Mar 2026 | Consolidated | 6.69 | 6.99 | +4.5% | 12 Jun 2026 (opens in a new tab) | 15 Jul 2026 (opens in a new tab) |
| Total expenses | Quarter to Mar 2026 | Consolidated | 6.89 | 7.19 | +4.4% | 12 Jun 2026 (opens in a new tab) | 15 Jul 2026 (opens in a new tab) |
| Profit before tax | Quarter to Mar 2026 | Consolidated | 0.38 | 0.08 | −78.6% | 12 Jun 2026 (opens in a new tab) | 15 Jul 2026 (opens in a new tab) |
| Net profit | Quarter to Mar 2026 | Consolidated | −1.72 | −2.02 | −17.5% | 12 Jun 2026 (opens in a new tab) | 15 Jul 2026 (opens in a new tab) |
| Profit before one-off items and tax | Quarter to Mar 2026 | Consolidated | 0.38 | 0.08 | −78.6% | 12 Jun 2026 (opens in a new tab) | 15 Jul 2026 (opens in a new tab) |
| Net profit from continuing businesses | Quarter to Mar 2026 | Consolidated | −1.72 | −2.02 | −17.5% | 12 Jun 2026 (opens in a new tab) | 15 Jul 2026 (opens in a new tab) |
| Total comprehensive income | Quarter to Mar 2026 | Consolidated | −1.80 | −2.10 | −16.6% | 12 Jun 2026 (opens in a new tab) | 15 Jul 2026 (opens in a new tab) |